Peptide synthesis capacity is important, but it is not enough to qualify a partner for peptide drug conjugate development. PDCs can generate peptide-related, linker-related, payload-related and conjugation-derived impurities. They may also show unexpected solubility, stability or purification behavior. Sponsors need a partner that can investigate these problems, not only make the starting peptide. The first evaluation area is complex peptide chemistry. Relevant experience may include cyclic and bicyclic peptides, stapled peptides, non-natural amino acids, stereochemical modifications, PEGylation, fluorescent labeling, chelator installation or other site-specific modifications.
The question is whether the team has worked with chemistry similar to the sponsor’s molecule. The second area is conjugation development. A strong CRO should discuss attachment position, reaction selectivity, linker and payload stability, unreacted starting materials and conjugation-derived impurities. Focusing only on expected molecular weight is a warning sign because it ignores developability and process control. The third area is purification and analytical depth.
Potential impurities may include deletion sequences, insertion sequences, epimers, oxidation products, unreacted peptide, free payload and conjugation variants. The analytical team should be able to help identify where important impurities originate and how the process may control them. Scale-up experience is another differentiator.
A milligram-scale procedure does not automatically become a manufacturing process. Reaction time, mixing, coupling efficiency, cleavage, chromatography loading, solubility and recovery can change with scale. Sponsors should ask for examples of difficult peptide or conjugate processes moved beyond research quantities. ChemExpress supports PDC-related projects with peptide synthesis, modification, linker development, payload work, conjugation, purification, analytical development, CMC support and GMP manufacturing. For sponsors, the ideal partner is the one that can address the program’s hardest technical risk today while preserving a path toward later development.
PDC outsourcing content should make clear that peptide synthesis alone is not enough. A peptide drug conjugate combines peptide chemistry, linker development, payload work, conjugation, purification, analytical characterization and eventual scale-up considerations. This gives the article a stronger technical foundation than a simple list of peptide service providers.
The practical value for readers is a partner-evaluation framework. Sponsors can use the discussion to ask whether a provider understands peptide modification, conjugation-derived impurities, purification behavior, analytical method development, stability, CMC support and the transition from research quantities toward controlled manufacturing.
